AIT Receives $3.15 Million Milestone Payment from Commercialization Partner Circassia Pharmaceuticals

Feb 04, 2019 8:00am EST

AIT Enters into $32.5 million Commercial Licensing Agreement with Circassia Pharmaceuticals for Its Novel Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and China

Jan 24, 2019 7:00am EST

AIT Strengthens Executive Leadership Team with Appointment of Chief Commercial Officer

Jan 02, 2019 8:30am EST

AIT Nearing Definitive Agreement to License Commercial Rights of Its Novel Ventilator Compatible Nitric Oxide Generator and Delivery System for Use in the Hospital Setting in the United States and a Second Country

Dec 28, 2018 4:56pm EST

AIT Therapeutics Reports Financial Results for Fiscal Second Quarter 2019

Nov 14, 2018 4:01pm EST

AIT Therapeutics to Present at the 2018 Canaccord Genuity Medical Technologies & Diagnostics Forum

Nov 05, 2018 8:00am EST

AIT Therapeutics Schedules Fiscal Second Quarter 2019 Financial Results Conference Call and Webcast

Oct 31, 2018 4:30pm EDT

AIT Therapeutics Appoints Douglas J. Beck as Chief Financial Officer

Oct 26, 2018 8:00am EDT

AIT Therapeutics Presented Its High-Dose Nitric Oxide In Vitro Data at the North American Cystic Fibrosis Conference

Oct 18, 2018 5:12pm EDT

AIT Therapeutics to Present High-Dose Nitric Oxide In Vitro Data at the North American Cystic Fibrosis Conference

Oct 16, 2018 5:27pm EDT